These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8419197)

  • 21. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Spanos E; Mantalenakis S
    Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome.
    Schoot DC; Hop WC; de Jong FH; van Dessel TJ; Fauser BC
    Fertil Steril; 1995 Dec; 64(6):1081-7. PubMed ID: 7589656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
    Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
    Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical significance of counting follicles in diagnosis of polycystic ovary syndrome by the three-dimensional ultrasound imaging with sonography based automated volume calculation method].
    He LR; Zhou LX; Pan RK; Zhang X
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):350-4. PubMed ID: 21733371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies.
    Ruiz A; Aguilar R; Tébar AM; Gaytán F; Sánchez-Criado JE
    Biol Reprod; 1996 Dec; 55(6):1284-91. PubMed ID: 8949885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Different Ovulation Induction Regimens on Sex Hormone Levels and Serum CTRP3 and CTRP15 Levels in Patients with Polycystic Ovary Syndrome (PCOS).
    Ren M; Liu J; Zhang Y; Fan L
    Biomed Res Int; 2022; 2022():6027878. PubMed ID: 35463985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian response to recombinant human follicle-stimulating hormone in luteinizing hormone-depleted women: examination of the two cell, two gonadotropin theory.
    Ben-Chetrit A; Gotlieb L; Wong PY; Casper RF
    Fertil Steril; 1996 Apr; 65(4):711-7. PubMed ID: 8654626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome.
    Anderson RE; Cragun JM; Chang RJ; Stanczyk FZ; Lobo RA
    Fertil Steril; 1989 Aug; 52(2):216-20. PubMed ID: 2502437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary response to bolus and continuous intravenous infusion of luteinizing hormone-releasing factor in normal women and women with polycystic ovarian syndrome.
    Mortimer RH; Lev-Gur M; Freeman R; Fleischer N
    Am J Obstet Gynecol; 1978 Mar; 130(6):630-4. PubMed ID: 345810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.
    Cook CL; Siow Y; Brenner AG; Fallat ME
    Fertil Steril; 2002 Jan; 77(1):141-6. PubMed ID: 11779604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency.
    Couzinet B; Lestrat N; Brailly S; Forest M; Schaison G
    J Clin Endocrinol Metab; 1988 Mar; 66(3):552-6. PubMed ID: 3127417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid.
    Mason HD; Willis DS; Beard RW; Winston RM; Margara R; Franks S
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1355-60. PubMed ID: 7962330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.
    Cheung AP; Pride SM; Yuen BH; Sy L
    Hum Reprod; 2002 Oct; 17(10):2540-7. PubMed ID: 12351525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low levels of follicle-stimulating hormone receptor-activation inhibitors in serum and follicular fluid from normal controls and anovulatory patients with or without polycystic ovary syndrome.
    Schipper I; Rommerts FF; Ten Hacken PM; Fauser BC
    J Clin Endocrinol Metab; 1997 May; 82(5):1325-31. PubMed ID: 9141511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cycle and hormone changes during perimenopause: the key role of ovarian function.
    Burger HG; Hale GE; Dennerstein L; Robertson DM
    Menopause; 2008; 15(4 Pt 1):603-12. PubMed ID: 18574431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease.
    van Weissenbruch MM; Schoemaker HC; Drexhage HA; Schoemaker J
    Hum Reprod; 1993 Jun; 8(6):813-21. PubMed ID: 8345068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.